Objective pulmonary arterial hypertension (pAH) is a severe complication of systemic sclerosis (ssc). in this longitudinal study, we aimed to identify factors associated with an unfavourable outcome in patients with ssc with early pAH (ssc-pAH) from the DeteCt cohort. Methods patients with ssc-pAH enrolled in DeteCt were observed for up to 3 years. Associations between cross-sectional variables and disease progression (defined as the occurrence of any of the following events: WHo Functional Class worsening, combination therapy for pAH, hospitalisation or death) were analysed by univariable logistic regression. results of 57 patients with pAH (median observation time 12.6 months), 25 (43.9%) had disease progression. the following factors (or (95% Ci)) were associated with disease progression: male gender (4.1 (1.2 to 14.1)), high forced vital capacity % predicted/carbon monoxide lung diffusion capacity (DLCo)% predicted ratio (3.6 (1.2 to 10.7)), high Borg Dyspnoea index (1.7 (1.1 to 2.6)) and low DLCo% predicted (non-linear relationship). Conclusion More than 40% of early-diagnosed patients with ssc-pAH had disease progression during a short follow-up time, with male gender, functional capacity and pulmonary function tests at pAH diagnosis being associated with progression. this suggests that even mild pAH should be considered a high-risk complication of ssc.
The DETECT study was the first multicentre, real-life study systematically using RHC in patients with SSc at increased risk to develop PAH. 4 In its cross-sectional stage, DETECT developed an algorithm able to select patients with SSc and a high suspicion of PAH for referral to RHC, minimising missed diagnoses in addition to identifying patients with milder PAH, in whom prompt institution of treatment might improve the disease course.
However, the prognosis of these patients with early detection of PAH has not been established to date. As part of the DETECT study, patients have been observed longitudinally for up to 3 years. This study reports on the longitudinal phase of the DETECT study, aiming to describe factors associated with an unfavourable outcome in patients with an early diagnosis of SSc-PAH.
PAtIents And MethOds data collection during the longitudinal stage of deteCt
The cross-sectional part of the DETECT study has been published. 4 Eighteen of the 62 centres involved in DETECT continued to follow up patients diagnosed with SSc-PAH at baseline on a yearly basis. The following data were recorded: survival status, reason for end of follow-up or death, WHO Functional Class (FC), PAH-related hospitalisation (>1 day) since last visit, 6 min walk distance, current or past treatment with PAH-specific therapies, including duration of therapy, and combination therapy. At the time of longitudinal data collection, combination therapy for PAH was used for more severe PAH, as the advantages of upfront combination therapy for PAH have emerged later. 5 Patients in WHO FC I and II are further referred to as having mild, or early, PAH.
statistical methods
Disease progression was defined by expert consensus as a composite outcome, based on the presence of at least one of the following events during follow-up: worsening in WHO FC from enrolment, presence of combination therapy for PAH, PAH-related hospitalisation and death from any cause.
The main analysis set comprises all patients with SSc-PAH who were included in the longitudinal stage of the DETECT study and who had available follow-up data. The complementary set of patients with SSc-PAH who could not be included in the longitudinal stage was used only for examining any potential selection bias that may have occurred. Two subgroups of the SSc-PAH analysis set were defined by the binary disease progression outcome, that is, 'With disease progression' (progressive PAH) or 'Without disease progression' (stable PAH).
Twenty-one of 121 baseline (cross-sectional) variables considered to be potential predictors of disease progression were selected for further analysis, based on input from the authors on feasibility of the variables and on their clinical relevance to PAH. Univariable logistic regression (ULR) analysis was performed using the binary disease progression outcome as dependent variable and the selected baseline variables as independent variables. ULR included the determination of OR and its 95% CI, and area under the receiver-operating characteristic curve (ROC-AUC) and its 95% CI. Accuracy of a predictor was considered fair if its AUC was >0.70. For each continuous baseline variable analysed by ULR, a quadratic term in the regression model was also included in order to examine a non-linear functional relationship with the outcome. A sensitivity analysis, excluding patients with missing outcome data, was also performed. The statistical analysis plan was developed and analyses were carried out by qualified statisticians using the SAS V.9.4 software.
results study cohort
Of the 145 patients with SSc-PAH identified in the DETECT study, 87 (60%) had PAH, of whom 57 patients had follow-up visits and the remaining 30 patients did not have follow-up visits (figure 1). Median time of follow-up was 12.6 months (range 2.4-35.8, IQR 10.7-21.7).
demographic and clinical characteristics
Using the composite definition of disease progression, 25/57 (43.9%) of patients with PAH with longitudinal data had progressive PAH and 32/57 (56.1%) had stable PAH. Demographics and clinical characteristics at enrolment of all, stable and progressive PAH patients, respectively, are displayed in table 1. Baseline mean pulmonary artery pressure was 32.5 (SD 8.3) mm Hg and 33/57 (57.9%) of patients were in WHO-FC I or II. Patients with stable PAH had a slightly longer follow-up, when compared with patients with progressive PAH ((months, mean, (Q1, Q3)): 13.0 (11.0, 21.6) vs 11.7 (10.2, 21.9)), but this difference was not significant (as shown by the overlapping 95% Hall-Wellner Bands of the Kaplan-Meier estimates,see online supplementary figure S1). Twenty-four of the 25 patients with progressive PAH and 28/32 patients with stable PAH received PAH treatment during follow-up. Four patients had missing data among the outcomes defining disease progression; they were included in the subgroup without disease progression (see table 1 ), but were excluded in the sensitivity analysis.
disease progression events
Among the 25 patients with disease progression, 4 died, 11 were hospitalised for PAH, 14 had at least one occurrence of worsening in WHO FC and 8 received PAH-specific combination treatment. Among the four patients who died, three died from a PAH-related cause (all in WHO FC III at enrolment), while the fourth died from severe pneumonia complicating surgery on the leg. Time to death in all cases was <12 months from baseline (range 2.4-10.5 months). Although the 1-year survival rate in this cohort was high (93%), there is some uncertainty as shown by the wide 95% Hall-Wellner Bands (online supplementary figure S1 ). 
Clinical and epidemiological research Factors associated with disease progression
Baseline factors potentially associated with PAH disease progression were analysed by ULR (table 2) . Male gender, high forced vital capacity (FVC)%/carbon monoxide lung diffusion capacity (DLCO)%, low DLCO% and high Borg Dyspnoea Index at enrolment were found to be significantly associated with disease progression. However, the first two had an AUC <0.70, denoting relatively poor performance as single predictors. The results of the sensitivity analysis were similar and are reported in the online supplementary materials.
dIsCussIOn
This study is the first longitudinal observation of a cohort of patients with SSc-PAH diagnosed by systematic RHC. 4 Most patients had mild or no PAH symptoms. None of these patients had been diagnosed with PH by RHC before study enrolment and the majority were in WHO FC I and II (33/57, 57.9%).
We observed that 25/57 patients (43.9%) had disease progression during a median follow-up of 12.6 months; 13/25 were in WHO FC I or II and 4/25 died during the first 12 months since PAH diagnosis (1-year survival rate 93%). This demonstrates that even mild PAH should be regarded as a high-risk complication of SSc.
The factors found to be associated with disease progression were male gender, lower DLCO%, higher FVC%/DLCO% ratio and higher Borg Dyspnoea Index. These factors are similar to risk factors identified for patients with more advanced PAH.
6-10 Low DLCO and male gender are independent, major risk factors for death in all patients with SSc, as shown in several large cohorts. [11] [12] [13] Higher FVC%/DLCO% ratio is a risk factor for *From the first non-Raynaud symptom. ACA, anticentromere antibodies; dcSSc, diffuse cutaneous SSc; DLCO, carbon monoxide lung diffusion capacity; FVC, forced vital capacity; mPAP, mean pulmonary artery pressure on RHC; NT-proBNP, N-terminal pro-(brain natriuretic peptide); PAH, pulmonary arterial hypertension; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; Q1, Q3=IQR; RHC, right-sided heart catheterisation; SSc, complication of systemic sclerosis; TR, tricuspid regurgitation.
PAH in patients with SSc, 4 and also suggests the absence of significant interstitial lung disease. Of note, patients in the DETECT cohort had, by enrolment criteria, DLCO<60% predicted and FVC>40% predicted; this has certainly influenced the FVC%/ DLCO% ratio, which was rather high in the entire DETECT cohort.
The risk factors identified by our exploratory analysis are highly feasible to use in clinical practice. Particular attention should be given to DLCO monitoring, both for PAH screening and prognostic purposes in patients with SSc (online supplementary tables S1 and S2).
One of the main strengths of this study is the uniqueness of the DETECT cohort, in which every patient underwent RHC at enrolment and had not been diagnosed with PAH before. High data quality was ensured by standardised echocardiographic and RHC protocols in all centres, with centralised laboratory testing and data management, and strict data quality monitoring. 4 The composite definition of disease worsening includes strong outcomes like death and hospitalisation due to PAH, adjudicated as per investigators' judgement.
One of the study limitations is the lack of longitudinal data in 30 patients with SSc-PAH from the original DETECT cohort. However, the baseline data displayed in table 1 show that these patients without follow-up data were in most aspects similar to patients with PAH having longitudinal data. Another potential limitation is the preselected nature of this cohort, limiting generalisation of our results. Although four patients in the PAH cohort had missing data on disease progression and were classified as having stable PAH, obtaining similar results in the sensitivity analysis which excluded these patients proved the validity of our results. Further potential limitations include the relatively short follow-up, the variability in PAH treatment due to the international, multicentre character of the study and the impossibility to perform multivariable analysis or to adjust the analysis for PAH treatment due to the small number of cases. The p value and ROC-AUC are from the ULR model with the quadratic functional form. Disease progression was defined as the presence of one of the following events: clinical worsening, combination PAH therapy, hospitalisation or death. All variables except gender, disease subset and ACA positivity have been analysed as linear terms. Results in bold characters are statistically significant. ACA, anticentromere antibodies; dcSSc, diffuse cutaneous SSc; DLCO, carbon monoxide lung diffusion capacity; FVC, forced vital capacity; lcSSc, limited cutaneous SSc; mPAP, mean pulmonary artery pressure on RHC; NT-proBNP, N-terminal pro-(brain natriuretic peptide); PAH, pulmonary arterial hypertension; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RHC, right-sided heart catheterisation; ROC-AUC, area under the receiver-operating characteristic curve; SSc, complication of systemic sclerosis; TR, tricuspid regurgitation; ULR, univariable logistic regression; US, ultrasonography.
In conclusion, the results of our study have practical implications, as they show that patients with early SSc-PAH have a meaningful rate of disease progression over a relatively short time, requiring close follow-up. Male patients with lower DLCO%, high FVC%/DLCO% and high Borg Dyspnoea Index might need particular attention.
